Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupFRA:6MD 83 3-Year EBITDA Growth Rate is 19.30% as of Dec. 2025, which is 86% above its 10-year median of 10.40. GuruFocus rates FRA:6MD with a GF Score™ of 83/100 and a GF Value™ of €179.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Medacta Group ranks better than 64.53% on this metric.
During the past 12 months, Medacta Group's average EBITDA Per Share Growth Rate was 22.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medacta Group was 25.00% per year. The lowest was -9.10% per year. And the median was 10.40% per year.
Medacta Group (FRA:6MD) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medacta Group 3-Year EBITDA Growth Rate Related Terms
FRA:6MD vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Medacta Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medacta Group's 3-Year EBITDA Growth Rate falls into.
Medacta Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.30% mean?
Medacta Group (FRA:6MD) has a 3-Year EBITDA Growth Rate of 19.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medacta Group and its competitors. This is 86% above median its historical median of 10.40. According to the industry distribution chart, Medacta Group ranks #244 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 35.5%.
Is Medacta Group's 3-Year EBITDA Growth Rate too high?
Medacta Group's current 3-Year EBITDA Growth Rate of 19.30% is 86% above median its 10-year median of 10.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Medacta Group's value of 19.30% is 144.3% above this industry median. Based on the distribution chart, Medacta Group ranks #244 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #244 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Medacta Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Medacta Group's value of 19.30% is 144.3% above this benchmark. While the company's 10-year median is 10.40 vs. the industry median of 7.90, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current 3-Year EBITDA Growth Rate of 19.30% is 144.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current 3-Year EBITDA Growth Rate is 19.30%, which is 86% above median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €179.31, compared to a current price of €131.00 — trading 26.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.30%, which is 86% above median its 10-year median of 10.40 and 144.3% above the Medical Devices & Instruments industry median of 7.90. Medacta Group's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current 3-Year EBITDA Growth Rate is 19.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (FRA:6MD) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of €131.00 is trading 26.9% below its estimated GF Value™ of €179.31.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for FRA:6MD:
3-Year EBITDA Growth Rate: 19.30% (86% above median its 10-year median of 10.40)
GF Value™: €179.31 vs. price of €131.00 (26.9% below fair value)
Industry Position: 144.3% above the Medical Devices & Instruments median (#244 of 688)
No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
83GF Score
Get the complete analysis for FRA:6MD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6MD has been successfully added to your 
